Diagnostic and Interventional Neuroradiology, University Medical Center Hamburg Eppendorf, Hamburg, Germany.
Radiology, University of Calgary, Calgary, Alberta, Canada.
J Neurointerv Surg. 2023 Mar;15(3):214-220. doi: 10.1136/neurintsurg-2021-018428. Epub 2022 Feb 24.
Analyses of the effect of pre-stroke functional levels on the outcome of endovascular therapy (EVT) have focused on the course of patients with moderate to substantial pre-stroke disability. The effect of complete freedom from pre-existing disability (modified Rankin Scale (mRS) 0) versus predominantly mild pre-existing disability/symptoms (mRS 1-2) has not been well delineated.
The HERMES meta-analysis pooled data from seven randomized trials that tested the efficacy of EVT. We tested for a multiplicative interaction effect of pre-stroke mRS on the relationship between treatment and outcomes. Ordinal regression was used to assess the association between EVT and 90-day mRS (primary outcome) in the subgroup of patients with pre-stroke mRS 1-2. Multivariable regression modeling was then used to test the effect of mild pre-stroke disability/symptoms on the primary and secondary outcomes (delta-mRS, mRS 0-2/5-6) compared with patients with pre-stroke mRS 0.
We included 1764 patients, of whom 199 (11.3%) had pre-stroke mRS 1-2. No interaction effect of pre-stroke mRS on the relationship between treatment and outcome was observed. Patients with pre-stroke mRS 1-2 had worse outcomes than those with pre-stroke mRS 0 (adjusted common OR (acOR) 0.53, 95% CI 0.40 to 0.70). Nonetheless, a significant benefit of EVT was observed within the mRS 1-2 subgroup (cOR 2.08, 95% CI 1.22 to 3.55).
Patients asymptomatic/without disability prior to onset have better outcomes following EVT than patients with mild disability/symptoms. Patients with pre-stroke mRS 1-2, however, more often achieve good outcomes with EVT compared with conservative management. These findings indicate that mild pre-existing disability/symptoms influence patient prognosis after EVT but do not diminish the EVT treatment effect.
对血管内治疗(EVT)结局的影响的分析集中在中重度卒中前功能障碍患者的病程上。完全没有既往残疾(改良 Rankin 量表(mRS)0 级)与主要轻度既往残疾/症状(mRS 1-2 级)的影响尚未明确。
HERMES 荟萃分析汇总了七项随机试验的数据,这些试验检验了 EVT 的疗效。我们检验了卒中前 mRS 对治疗与结局之间关系的乘法交互效应。有序回归用于评估 EVT 与 90 天 mRS(主要结局)在卒中前 mRS 1-2 级亚组中的相关性。多变量回归模型用于检验轻度卒中前残疾/症状与主要和次要结局(delta-mRS、mRS 0-2/5-6)的关系,与卒中前 mRS 0 级的患者进行比较。
我们纳入了 1764 名患者,其中 199 名(11.3%)患者卒中前 mRS 1-2 级。卒中前 mRS 对治疗与结局之间关系没有交互效应。卒中前 mRS 1-2 级的患者结局比卒中前 mRS 0 级的患者差(调整后的常见比值比(acOR)0.53,95%CI 0.40 至 0.70)。然而,在 mRS 1-2 级亚组中观察到 EVT 有显著获益(cOR 2.08,95%CI 1.22 至 3.55)。
在 EVT 治疗后,无残疾/无症状的患者比有轻度残疾/症状的患者结局更好。然而,与保守治疗相比,卒中前 mRS 1-2 级的患者更常通过 EVT 获得良好结局。这些发现表明,轻度的既往残疾/症状影响 EVT 治疗后的患者预后,但不会降低 EVT 的治疗效果。